Our results were consistent with the reports that miR-410 negatively regulated pRb/E2F pathway by directly targeting CDK1 and was an oncogene in breast cancer [29], and that miR-410 was highly expressed in liver and colorectal tumors, and enhanced tumor cell growth by silencing FHL1 and thus served as oncomiR [33]. The gene discussed is CDK1; the disease is breast cancer.